← Leaderboards
William Thomas Shearer
Baylor College Of Medicine
$34,592,326
Attributed
$34,592,326
Total exposure
137
Grants
94
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.6M · FY2005–15$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$34,592,326 · 137
By mechanism
U01$18,140,688 · 4
M01$7,628,231 · 127
T32$2,794,752 · 1
P30$2,119,491 · 3
R01$2,004,755 · 1
UM1$1,904,409 · 1
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Elizabeth Chiao$12,842,422
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchResourcesSourceUnited States National Institutes Of HealthFundingResearch PersonnelGrantHiv InfectionsChildClinical TrialsComputer Retrieval Of Information On Scientific Projects DatabaseHuman SubjectInstitutionPediatric AidsAids TherapyHuman Therapy EvaluationAdolescentSafetyDoseHiv-1Protocols DocumentationAdultResponsePlasma
Grant awards (200)
Clinical Research Core$88,808
P30 · FY2015 · AI · contact PI
Clinical Research Core$256,177
P30 · FY2014 · AI · contact PI
Baylor College of Medicine Clinical Trial Unit$944,697
UM1 · FY2013 · AI · contact PI
Clinical Research Core$229,787
P30 · FY2013 · AI · contact PI
Baylor College of Medicine Clinical Trial Unit$959,712
UM1 · FY2012 · AI · contact PI
Clinical Research Core$239,522
P30 · FY2012 · AI · contact PI
Training Program for Clinical Research on AIDS$234,828
T32 · FY2012 · AI · contact PI
Baylor College of Medicine Clinical Trial Unit$770,321
U01 · FY2011 · AI · contact PI
Clinical Research Core$269,425
P30 · FY2011 · AI · contact PI
Training Program for Clinical Research on AIDS$242,666
T32 · FY2011 · AI · contact PI
CLINICAL TRIAL: P1025 PERINATAL CORE PROTOCOL VERSION 10$111,684
M01 · FY2011 · RR · contact PI
PHACS PH 100 SURVEILLANCE MONITORING FOR ART TOXICITIES STUDY IN HIV-UNINFEC$103,769
M01 · FY2011 · RR · contact PI
H-19197 PHACS PH 200 ADOLESCENT MASTER PROTOCOL (AMP)$81,785
M01 · FY2011 · RR · contact PI
PACTG P1026S (VERSION 20), PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUG$41,333
M01 · FY2011 · RR · contact PI
A5240 (VERSION 10) A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY$26,382
M01 · FY2011 · RR · contact PI
PH 201 MEMORY FUNCTIONING IN CHILDREN AND ADOLESCENTS WITH PERINATAL HIV$14,951
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: IMPAACT P1086 (VS 10) A PHASE II STUDY TO ASSESS THE SAFETY AN$14,951
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: IMPAACT P1088 (VERSION 10) A PHASE II STUDY TO ASSESS THE SAFET$11,431
M01 · FY2011 · RR · contact PI
IMPAACT 1077HS (VS 10) HAART STANDARD VERSION OF THE PROMISE STUDY$7,915
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: IMPAACT P1066 (VERSION 10) A PHASE I/II, MULTICENTER, OPEN-LAB$7,036
M01 · FY2011 · RR · contact PI
A5241 (VERSION 10) THE OPTIMIZED TREATMENT THAT INCLUDES OR OMITS NRTIS$5,276
M01 · FY2011 · RR · contact PI
DURATION OF HUMAN PAPILLOMA VIRUS (HPV) TYPE-SPECIFIC ANTIBODY$2,638
M01 · FY2011 · RR · contact PI
IMPAACT P1089 (VERSION 10) A LABORATORY STUDY TO ASSESS THE IMMUNOGENICITY$1,760
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: IMPAACT 1065 PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF Q$1,755
M01 · FY2011 · RR · contact PI
Baylor College of Medicine Clinical Trial Unit$784,766
U01 · FY2010 · AI · contact PI
Clinical Research Core$240,124
P30 · FY2010 · AI · contact PI
Training Program for Clinical Research on AIDS$163,952
T32 · FY2010 · AI · contact PI
Baylor College of Medicine Clinical Trial Unit$153,500
U01 · FY2010 · AI · contact PI
CLINICAL TRIAL: P1025 PERINATAL CORE PROTOCOL VERSION 10$110,354
M01 · FY2010 · RR · contact PI
H-19197 PHACS PH 200 ADOLESCENT MASTER PROTOCOL (AMP)$107,059
M01 · FY2010 · RR · contact PI
PHACS PH 100 SURVEILLANCE MONITORING FOR ART TOXICITIES STUDY IN HIV-UNINFEC$97,176
M01 · FY2010 · RR · contact PI
SLEEP STUDIES IN HIV OLDER CHILDREN/ADOLESCENTS$27,177
M01 · FY2010 · RR · contact PI
A5240 (VERSION 10) A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY$15,646
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: IMPAACT 1065 PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF QU$14,824
M01 · FY2010 · RR · contact PI
PACTG P1026S (VERSION 20), PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUG$14,824
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: IMPAACT P1086 (VS 10) A PHASE II STUDY TO ASSESS THE SAFETY AN$12,353
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: IMPAACT P1088 (VERSION 10) A PHASE II STUDY TO ASSESS THE SAFET$10,705
M01 · FY2010 · RR · contact PI
A5241 (VERSION 10) THE OPTIMIZED TREATMENT THAT INCLUDES OR OMITS NRTIS$8,235
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: PACTG 390-COMBINATION ANTIRETROVIRAL REGIMENS IN ANTIRETROVIRAL$5,764
M01 · FY2010 · RR · contact PI
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SAFETY$4,118
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: IMPAACT P1066 (VERSION 10) A PHASE I/II, MULTICENTER, OPEN-LABE$1,651
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: PHASE II SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT HUMAN P$1,648
M01 · FY2010 · RR · contact PI
Baylor College of Medicine Clinical Trial Unit$741,043
U01 · FY2009 · AI · contact PI
Clinical Research Core$269,315
P30 · FY2009 · AI · contact PI
Training Program for Clinical Research on AIDS$262,156
T32 · FY2009 · AI · contact PI
CLINICAL TRIAL: P1025 PERINATAL CORE PROTOCOL VERSION 10$183,741
M01 · FY2009 · RR · contact PI
SLEEP STUDIES IN HIV OLDER CHILDREN/ADOLESCENTS$157,307
M01 · FY2009 · RR · contact PI
H-19197 PHACS PH 200 ADOLESCENT MASTER PROTOCOL (AMP)$150,696
M01 · FY2009 · RR · contact PI
PHACS PH 100 SURVEILLANCE MONITORING FOR ART TOXICITIES STUDY IN HIV-UNINFEC$122,936
M01 · FY2009 · RR · contact PI
PACTG P1026S (VERSION 20), PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUG$116,325
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: IMPAACT 1065 PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF QU$38,336
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PACTG 390-COMBINATION ANTIRETROVIRAL REGIMENS IN ANTIRETROVIRAL$17,183
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE II SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT HUMAN P$15,863
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: IMPAACT P1066 VERSION 1 A PHASE I/II, MULTICENTER, OPEN-LABEL$14,542
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PACTG P1051, A MULTIPLE-DOSE, OPEN-LABEL RANDOMIZED, SAFETY AND$10,576
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PACTG 1020-A (VERSION 20):PHASE I/II STUDY OF A NOVEL PROTEASE$3,966
M01 · FY2009 · RR · contact PI
CARDIOVASCULAR STATUS OF HAART THERAPY IN HIV-INFECTED CHILDREN (NON-WITS HAA$1,321
M01 · FY2009 · RR · contact PI
Baylor College of Medicine Clinical Trial Unit$954,755
U01 · FY2008 · AI · contact PI
CLINICAL TRIAL: P1025 PERINATAL CORE PROTOCOL VERSION 10$444,787
M01 · FY2008 · RR · contact PI
Training Program for Clinical Research on AIDS$259,602
T32 · FY2008 · AI · contact PI
SLEEP STUDIES IN HIV OLDER CHILDREN/ADOLESCENTS$258,268
M01 · FY2008 · RR · contact PI
Clinical Research Core$158,505
P30 · FY2008 · AI · contact PI
CLINICAL TRIAL: IMPAACT 219: (VERSION 40) PEDIATRIC LATE OUTCOMES PROTOCOL$137,107
M01 · FY2008 · RR · contact PI
PHACS PH 100 SURVEILLANCE MONITORING FOR ART TOXICITIES STUDY IN HIV-UNINFEC$84,497
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: IMPAACT 1065 PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF QU$65,366
M01 · FY2008 · RR · contact PI
PACTG P1026S (VERSION 20), PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUG$46,235
M01 · FY2008 · RR · contact PI
H-19197 PHACS PH 200 ADOLESCENT MASTER PROTOCOL (AMP)$27,104
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE II SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT HUMAN P$22,321
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PACTG P1051, A MULTIPLE-DOSE, OPEN-LABEL RANDOMIZED, SAFETY AND$15,941
M01 · FY2008 · RR · contact PI
CARDIOVASCULAR STATUS OF HAART THERAPY IN HIV-INFECTED CHILDREN (NON-WITS HAA$15,941
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PACTG 1020-A (VERSION 20):PHASE I/II STUDY OF A NOVEL PROTEASE I$14,348
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PACTG 390-COMBINATION ANTIRETROVIRAL REGIMENS IN ANTIRETROVIRAL$14,348
M01 · FY2008 · RR · contact PI
CARDIAC STATUS OF HAART EXPOSED INFANTS OF HIV-INFECTED MOTHERS$3,190
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: IMPAACT 382 (VERSION 50) A PHASE I/II, OPEN-LABEL, AUC-CONTROLLE$1,593
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PACTG 1039 (VERSION 10) A PHASE III RANDOMIZED TRIAL OF THE SAFE$1,593
M01 · FY2008 · RR · contact PI
P1034 (VERSION 10) A COMPARATIVE TRIAL OF PROTEASE-CONTAINING AND PROTEASE-S$1,593
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: IMPAACT P1066 (VERSION 10) A PHASE I/II, MULTICENTER, OPEN-LABEL$1,593
M01 · FY2008 · RR · contact PI
Baylor College of Medicine Clinical Trial Unit$1,516,705
U01 · FY2007 · AI · contact PI
Sleep Studies in HIV+ Older Children/Adolescents$448,609
R01 · FY2007 · HL · contact PI
P1025 PERINATAL CORE PROTOCOL VERSION 10 (HIV)$281,231
M01 · FY2007 · RR · contact PI
SLEEP STUDIES IN HIV OLDER CHILDREN/ADOLESCENTS$258,587
M01 · FY2007 · RR · contact PI
ACTG 219: PEDIATRIC LATE OUTCOMES-INFANTS AND CHILDREN WITH HIV INFECTION$169,213
M01 · FY2007 · RR · contact PI
PACTG P1026S (VERSION 20), PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUG (HI$48,859
M01 · FY2007 · RR · contact PI
CARDIAC STATUS OF HAART EXPOSED INFANTS OF HIV-INFECTED MOTHERS$28,600
M01 · FY2007 · RR · contact PI
PACTG 1020-A (VERSION 20):PHASE I/II STUDY OF A NOVEL PROTEASE INHIBITOR IN HIV$17,875
M01 · FY2007 · RR · contact PI
PACTG 390-COMBINATION ANTIRETROVIRAL REGIMENS IN ANTIRETROVIRAL NANVE CHILDREN$13,109
M01 · FY2007 · RR · contact PI
PACTG 1039 (VERSION 10) A PHASE III RANDOMIZED TRIAL OF THE SAFETY AND ANTIR$11,915
M01 · FY2007 · RR · contact PI
WOMEN & INFANTS TRANSMISSION STUDY III (HIV)$10,725
M01 · FY2007 · RR · contact PI
P1034 (VERSION 10) A COMPARATIVE TRIAL OF PROTEASE-CONTAINING AND PROTEASE-S$10,725
M01 · FY2007 · RR · contact PI
PHASE II SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT HUMAN PAPILLOMAVIRUS$10,725
M01 · FY2007 · RR · contact PI
AN OPEN-LABEL STUDY TO EVALUATE PHARMACOKINETICS OF EMTRICITABINE$9,533
M01 · FY2007 · RR · contact PI
ACTG 382: ANTIVIRAL ACTIVITY OF DMP 266 WITH NELFINAVIR IN CHILDREN (HIV)$8,340
M01 · FY2007 · RR · contact PI
PACTG P1051, A MULTIPLE-DOSE, OPEN-LABEL RANDOMIZED, SAFETY AND PHARMACOKINET$8,340
M01 · FY2007 · RR · contact PI
Pediatric Clinical Trials Program for AIDS$479,940
U01 · FY2006 · AI · contact PI
Sleep Studies in HIV+ Older Children/Adolescents$451,978
R01 · FY2006 · HL · contact PI
Training Program for Clinical Research on AIDS$254,687
T32 · FY2006 · AI · contact PI
WOMEN & INFANTS TRANSMISSION STUDY III (HIV)$223,168
M01 · FY2006 · RR · contact PI
Sleep Studies in HIV+ Older Children/Adolescents$165,000
R01 · FY2006 · HL · contact PI
SLEEP STUDIES IN HIV OLDER CHILDREN/ADOLESCENTS$145,207
M01 · FY2006 · RR · contact PI
P1025 PERINATAL CORE PROTOCOL VERSION 10 (HIV)$125,715
M01 · FY2006 · RR · contact PI
ACTG 219: PEDIATRIC LATE OUTCOMES-INFANTS AND CHILDREN WITH HIV INFECTION$120,842
M01 · FY2006 · RR · contact PI
CARDIAC STATUS OF HAART EXPOSED INFANTS OF HIV-INFECTED MOTHERS$48,728
M01 · FY2006 · RR · contact PI
PACTG P1051, A MULTIPLE-DOSE, OPEN-LABEL RANDOMIZED, SAFETY AND PHARMACOKINET$15,592
M01 · FY2006 · RR · contact PI
ACTG 382: ANTIVIRAL ACTIVITY OF DMP 266 WITH NELFINAVIR IN CHILDREN (HIV)$13,644
M01 · FY2006 · RR · contact PI
PACTG 1020-A (VERSION 20):PHASE I/II STUDY OF A NOVEL PROTEASE INHIBITOR IN HIV$12,668
M01 · FY2006 · RR · contact PI
PACTG 390-COMBINATION ANTIRETROVIRAL REGIMENS (HIV)$8,771
M01 · FY2006 · RR · contact PI
PACTG P1026S (VERSION 20), PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRALS (HIV)$7,797
M01 · FY2006 · RR · contact PI
INFLUZENZA VACCINE (FLUMIST) IN HIV-INFECTED CHILDREN$7,797
M01 · FY2006 · RR · contact PI
PACTG P1045 (VERSION 10) PREVALENCE OF MORPHOLOGIC AND METABOLIC ABNORMALITI$6,821
M01 · FY2006 · RR · contact PI
P1034 (VERSION 10) A COMPARATIVE TRIAL OF PROTEASE-CONTAINING AND PROTEASE-S$5,847
M01 · FY2006 · RR · contact PI
AN OPEN-LABEL STUDY TO EVALUATE PHARMACOKINETICS OF EMTRICITABINE$5,847
M01 · FY2006 · RR · contact PI
P1042S (VERSION 10) COGNITIVE, BEHAVIORAL AND PSYCHOSOCIAL CORRELATES OF MED$4,874
M01 · FY2006 · RR · contact PI
PACTG 1039 (VERSION 10) A PHASE III RANDOMIZED TRIAL OF THE SAFETY AND ANTIR$4,874
M01 · FY2006 · RR · contact PI
P1022 RANDOMIEZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS SPARING REGIMEN$1,947
M01 · FY2006 · RR · contact PI
PACTG P1006 THE EFFECTS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) ON TH$974
M01 · FY2006 · RR · contact PI
Pediatric Clinical Trials Program for AIDS$1,264,879
U01 · FY2005 · AI
WOMEN AND INFANTS TRANSMISSION STUDY (WITSIV)$797,141
U01 · FY2005 · HD
Sleep Studies in HIV+ Older Children/Adolescents$465,212
R01 · FY2005 · HL
WOMEN &INFANTS TRANSMISSION STUDY III- HIV$321,655
M01 · FY2005 · RR
Training Program for Clinical Research on AIDS$267,679
T32 · FY2005 · AI
P1025 PERINATAL CORE PROTOCOL VERSION 10, HIV$136,933
M01 · FY2005 · RR
ACTG 219: PEDIATRIC LATE OUTCOMES-INFANTS AND CHILDREN WITH HIV INFECTION$129,580
M01 · FY2005 · RR
CARDIAC STATUS OF HAART EXPOSED INFANTS OF HIV-INFECTED MOTHERS$47,787
M01 · FY2005 · RR
PACTG 390-COMBINATION ANTIRETROVIRAL REGIMENS IN ANTIRETROVIRAL NAIVE PED, HIV$36,759
M01 · FY2005 · RR
PACTG 1020-A (VERSION 20):PHASE I/II STUDY OF A NOVEL PROTEASE INHIBITOR IN HIV$23,895
M01 · FY2005 · RR
PACTG P1051, PHARMACOKINETIC PHARMACOKINETIC STUDY OF TIPRANAVIR- PED HIV$19,299
M01 · FY2005 · RR
SAFETY AND IMMUNOGENICITY OF COLD ADAPTED INFLUENZA VACCINE IN HIV-INFECTED$13,785
M01 · FY2005 · RR
AN OPEN-LABEL STUDY TO EVALUATE PHARMACOKINETICS OF EMTRICITABINE$12,867
M01 · FY2005 · RR
ACTG 382: ANTIVIRAL ACTIVITY OF DMP 266 WITH NELFINAVIR IN CHILDREN W/ HIV$11,946
M01 · FY2005 · RR
P1022 RANDOMIZED TRIAL OF PROTEASE INHIBITOR- SPARING REGIMENS- HIV$11,028
M01 · FY2005 · RR
SLEEP STUDIES IN HIV OLDER CHILDREN/ADOLESCENTS$8,271
M01 · FY2005 · RR
ACTG 381 (VERSION 10): MAINTENANCE OF LONG-TERM UNDETECTABLE PLASMA HIV-1 RNA$5,514
M01 · FY2005 · RR
PACTG P1010 (VERSION 10): EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION$4,596
M01 · FY2005 · RR
PACTG P1045 -PREVALENCE OF MORPHOLOGIC AND METABOLIC ABNOR W/ PED HIV$4,596
M01 · FY2005 · RR
PACTG P1013 A PHASE I/II TRIAL OF RITONAVIR AND INDINAVIR IN CHILDREN- HIV$2,757
M01 · FY2005 · RR
COGNITIVE, BEHAVIORAL AND PSYCHOSOCIAL CORRELATES OF MEDICATION ADHERENCE IN HIV$2,757
M01 · FY2005 · RR
Pediatric Clinical Trials Program for AIDS$1,162,490
U01 · FY2004 · AI
WOMEN AND INFANTS TRANSMISSION STUDY (WITSIV)$765,747
U01 · FY2004 · HD
Sleep Studies in HIV+ Older Children/Adolescents$473,956
R01 · FY2004 · HL
WOMEN &INFANTS TRANSMISSION STUDY III$405,390
M01 · FY2004 · RR
Training Program for Clinical Research on AIDS$260,694
T32 · FY2004 · AI
ACTG 219: Pediatric Late Outcomes-Infants and Children with HIV Infection$139,671
M01 · FY2004 · RR
P1025 PERINATAL CORE PROTOCOL VERSION 1.0$103,333
M01 · FY2004 · RR
CARDIAC STATUS OF HAART EXPOSED INFANTS OF HIV-INFECTED MOTHERS$68,132
M01 · FY2004 · RR
ACTG 351: PHASE I/II TRIAL OF CD4-IGG2 IN HIV-INFECTED C$64,726
M01 · FY2004 · RR
PACTG 1020-A (version 2.0):Phase I/II Protease Inhibitor$52,234
M01 · FY2004 · RR
ACTG 382: ANTIVIRAL ACTIVITY OF DMP 266 WITH NELFINAVIR IN CHILDREN$29,525
M01 · FY2004 · RR
P1022 RANDOMIZED TRIAL OF PROTEASE INHIBITOR-INCLUDING$22,712
M01 · FY2004 · RR
ACTG 381 (Version 1.0): Maintenance of Long-Term Undetectable Plasma HIV-1 RNA$13,626
M01 · FY2004 · RR
OPEN-LABEL STUDY OF PHARMACOKINETICS OF EMTRICITABINE$11,354
M01 · FY2004 · RR
PACTG 390-COMBINATION ANTIRETROVIRAL REGIMENS IN ANTIRETROVIRAL NANVE CHILDREN$9,085
M01 · FY2004 · RR
PACTG P1013 A PHASE I/II TRIAL OF RITONAVIR /INDINAVIR$9,085
M01 · FY2004 · RR
ACTG 356: ZDV/3TC/NEVIRAPINE AND ZDV/3TC/NEVIRAPINE/1592U89 COMBINATION THERAPY$4,541
M01 · FY2004 · RR
P1008: RATE OF OPPORTUNISTIC INFECTION EVENTS IN HIV$4,541
M01 · FY2004 · RR
ACTG P1010 (VERSION 1.0): ANTIRETROVIRAL THERAPY /BODY C$2,272
M01 · FY2004 · RR
PACTG 1024 (Version 1.0): Immunogenicity of PCV in HIV with HAART$1,134
M01 · FY2004 · RR
ACTG358: PHASE I TRIAL OF INDINAVIR$1,134
M01 · FY2004 · RR
Pediatric Clinical Trials Program for AIDS$1,630,636
U01 · FY2003 · AI
WOMEN AND INFANTS TRANSMISSION STUDY (WITSIV)$735,451
U01 · FY2003 · HD
Training Program for Clinical Research on AIDS$265,986
T32 · FY2003 · AI
Pediatric Clinical Trials Program for AIDS$1,219,019
U01 · FY2002 · AI
WOMEN AND INFANTS TRANSMISSION STUDY (WITSIV)$706,482
U01 · FY2002 · HD
Training Program for Clinical Research on AIDS$250,369
T32 · FY2002 · AI
CORE--CLINICAL RESEARCH FACILITY$129,540
P30 · FY2002 · AI
PEDIATRIC AIDS CLINICAL TRIALS PROGRAM$1,212,235
U01 · FY2001 · AI
WOMEN AND INFANTS TRANSMISSION STUDY (WITS IV)$687,769
U01 · FY2001 · HD
TRAINING PROGRAM FOR CLINICAL RESEARCH ON AIDS$173,258
T32 · FY2001 · AI
ACTG377:PHASE II PRAM OF NOVEL ANTIRETROVIRAL THERAPY IN STABLE HIV C$155,764
M01 · FY2001 · RR
ACTG358:PHASE I TRIAL OF SAFETY,TOLERANCE, &PHARMACOKINETICS OF ORAL$155,764
M01 · FY2001 · RR
ACTG 356:ZDV &3TC &NEVIRAPINE &ZDV &3TC &NEVIRAPINE &1592U89 CO$155,764
M01 · FY2001 · RR
ACTG366:PHASEI &II MASTER PROT OF NOVEL ANTIRETROVIRAL COMBINATION T$155,764
M01 · FY2001 · RR
ACTG382:STUDY TO DETERMINE PHARMACOKINETICS, OF DMP266 W/ NELFINAVIR$155,764
M01 · FY2001 · RR
CORE--CLINICAL RESEARCH FACILITY$129,540
P30 · FY2001 · AI
IMMUNE FACTORS IN PEDIATRIC LONG-TERM HIV SURVIVORS$0
M01 · FY2001 · RR
CORE--CLINICAL RESEARCH FACILITY$0
P30 · FY2001 · AI
NOCTURNAL ASTHMA, CHRONOBIOLOGY AND SLEEP--PILOT STUDY$0
M01 · FY2001 · RR
ACTG 316--NEVIRAPINE FOR PREVENTION OF MATERNAL/FETAL TRANSMISSION IN HIV$0
M01 · FY2001 · RR
ACTG 247--INCREASED CALORIC DENSITY INFANT FORMULA IN HIV INFECTED INFANTS$0
M01 · FY2001 · RR
ACTG225--COMPARATIVE STUDY/SEROCONVERSION OF MEASLES VACCINATIONS/HIV + CHILDREN$0
M01 · FY2001 · RR
ACTG254--AT/AZ COMPARED TO TMP/SMX PREVENTING BACTERIAL INFECTIONS/HIV+ CHILDREN$0
M01 · FY2001 · RR
WOMEN AND INFANTS TRANSMISSION STUDY$0
M01 · FY2001 · RR
ACTG219--PEDIATRIC LATE OUTCOMES--INFANTS AND CHILDREN WITH HIV INFECTION$0
M01 · FY2001 · RR
PEDIATRIC HEART AND LUNG COMPLICATIONS OF HIV INFECTION$0
M01 · FY2001 · RR
PEDIATRIC AIDS CLINICAL TRIALS PROGRAM$1,308,707
U01 · FY2000 · AI
WOMEN AND INFANTS TRANSMISSION STUDY (WITSIII)$1,249,102
U01 · FY2000 · AI
TRAINING PROGRAM FOR CLINICAL RESEARCH ON AIDS$158,875
T32 · FY2000 · AI
CORE--CLINICAL RESEARCH FACILITY$108,748
P30 · FY2000 · AI
ACTG219--PEDIATRIC LATE OUTCOMES--INFANTS AND CHILDREN WITH HIV INFECTION$35,952
M01 · FY2000 · RR
PEDIATRIC HEART AND LUNG COMPLICATIONS OF HIV INFECTION$35,952
M01 · FY2000 · RR
ACTG382:STUDY TO DETERMINE PHARMACOKINETICS, OF DMP266 W/ NELFINAVIR$35,952
M01 · FY2000 · RR
ACTG377:PHASE II PRAM OF NOVEL ANTIRETROVIRAL THERAPY IN STABLE HIV C$35,952
M01 · FY2000 · RR
ACTG366:PHASEI &II MASTER PROT OF NOVEL ANTIRETROVIRAL COMBINATION T$35,952
M01 · FY2000 · RR
ACTG358:PHASE I TRIAL OF SAFETY,TOLERANCE, &PHARMACOKINETICS OF ORAL$35,952
M01 · FY2000 · RR
ACTG 356:ZDV &3TC &NEVIRAPINE &ZDV &3TC &NEVIRAPINE &1592U89 CO$35,952
M01 · FY2000 · RR
ACTG 351:A PHASE I &II TRIAL OF CD4 IGG2 IN HIV INFECTED CHILDREN$35,952
M01 · FY2000 · RR
ACTG 338--FRAM OF ANTIRETROVIRAL THERAPY IN HIV INFECTED CHILDREN$35,952
M01 · FY2000 · RR
ACTG 316--NEVIRAPINE FOR PREVENTION OF MATERNAL/FETAL TRANSMISSION IN HIV$35,952
M01 · FY2000 · RR
TRIAL OF RECOMBINANT INTERLEUKIN 2 IN SYMPTOMATIC HIV INFECTED CHILDREN$35,952
M01 · FY2000 · RR
ACTG 247--INCREASED CALORIC DENSITY INFANT FORMULA IN HIV INFECTED INFANTS$35,952
M01 · FY2000 · RR
ACTG225--COMPARATIVE STUDY/SEROCONVERSION OF MEASLES VACCINATIONS/HIV + CHILDREN$35,952
M01 · FY2000 · RR